Browsing by Author van Hazel, Guy

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 10 of 10
Issue DateTitleAuthor(s)Citation
2013Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17Pavlakis, Nick; Simes, Robert John; Blondal, J; Burkes, R L; Gibbs, Peter; Jonker, D; Karapetis, Christos; Lee, U; Meharchand, J; Moore, Malcolm; O'Callaghan, Chris; Price, T.J.; Rubin, S; Shapiro, Jeremy; Tebbutt, Niall C; Tu, Dongsheng; van Hazel, Guy; Vickers, M; Zalcberg, John; Zhu, L; Northern Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials CentreAssociation of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17, Annals of Oncology, vol.24, 4, 2013,pp 953-960
2010Capecitabine, Bevacizumab and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized, Phase III MAX Study.Gebski, Val; Simes, Robert John; Stockler, Martin; Zannino, Diana; Ackland, Stephen P.; Broad, Adam; Chua, Yu Jo; Cummins, Michelle; Cunningham, David; Forgeson, Garry; Ganju, Vinod; Price, Timothy; Robinson, Bridget; Saunders, M; Tebbutt, Niall C; van Hazel, Guy; Wilson, Kate; Zalcberg, J; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreCapecitabine, Bevacizumab and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized, Phase III MAX Study., Journal of Clinical Oncology (Online), vol.28, 19,pp 3191-3198
2007Cetuximab for the Treatment of Colorectal CancerSimes, Robert John; Zalcberg, John; Au, Heather Jane; Berry, Scott R.; et, al; Jonker, Derek J.; Karapetis, Christos (Chris); Krahn, Marianne; O’Callaghan, Chris J.; Price, Timothy; Tebbutt, Niall C; Tu, Dongsheng; van Hazel, Guy; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreCetuximab for the Treatment of Colorectal Cancer, New England Journal of Medicine, vol.357,(20),2007,pp 2040-2048
2015Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancerGebski, Val; Lee, Chee Khoon; Mann, Kristy; Simes, Robert John; Wilson, Kate; Bruhn, M; Cunningham, David; Hardingham, Jennifer; Price, Timothy; Robinson, B; Tebbutt, Niall; Townsend, Amanda; van Hazel, Guy; Weickhardt, Andrew; Wrin, Joseph; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreCorrelation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer, British Journal of Cancer, vol.112, 6, 2015,pp 963-970
2013Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trialGebski, Val; Parry, M M; Pavlakis, Nick; Zannino, Diana; Dobrovic, Alexander N; Ganju, V.; Mellor, D; Strickland, A. H.; Tebbutt, Niall C; van Hazel, Guy; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Northern Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials CentreDocetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial, British Journal of Cancer, vol.108, 4, 2013,pp 771-774
2010Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomasBrown, Christopher; Gainford, Mary; Gebski, Val; Miller, Danielle; Abdi, Ehtesham A; Ackland, Stephen P.; Goldstein, D; Jefford, Michael; Selva-Nayagam, Sid; Shannon, Jenny; Tebbutt, Niall C; van Hazel, Guy; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreFixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas, Cancer Chemotherapy and Pharmacology, vol.0, 0,pp 1-7
2012The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancerBrown, Christopher; Gebski, Val; Horvath, Lisa; Hruby, George; Ackland, Stephen P.; Borg, M; Carroll, Susan; Cummins, Michelle M; et al, Various; Goldstein, David; Selva-Nayagam, Sid; Shapiro, Jeremy; Spry, Nigel.A.; van Hazel, Guy; Wratten, C.; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Central Clinical School: Medicine; Central Clinical School: MedicineThe GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer, British Journal of Cancer, vol.106, 1, 2012,pp 61-69
2010Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trialCummins, Michelle; Gebski, Val; Sourjina, Tatiana; Stockler, Martin; Ganju, Vinod; Gibbs, David; Strickland, A. H.; Tebbutt, Niall C; van Hazel, Guy; Zalcberg, John; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreRandomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial, British Journal of Cancer, vol.102, 3,pp 475-481
2006A randomized trial of capecitabine given intermittently versus continuously versus classical CMF as first line chemotherapy for women with advanced breast cancer unsuited to more intensive treatmentCoates, Alan; Gebski, Val; Simes, Robert John; Sourjina, Tatiana; Stockler, Martin; Ackland, Stephen P.; Byrne, Michael J.; Finch, K; Fitzharris, B; Forbes, John F.; Frances, P; Harvey, V; Kato-Fong, A; Lindsay, Dianne; Paksec, Lisa; van Hazel, Guy; School of Public Health: Public Health; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreA randomized trial of capecitabine given intermittently versus continuously versus classical CMF as first line chemotherapy for women with advanced breast cancer unsuited to more intensive treatment, Breast Cancer Research and Treatment, vol.100, Supplement 1,pp S278-S278
2011Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysisBoland, Amy L.; Brown, Christopher; Clarke, Stephen; Gebski, Val; Simes, Robert John; Yip, Sonia; Buck, M; Goldstein, David; Jeffrey, G. Mark; Lowenthal, Raymond M.; Ransom, David T.; Tebbutt, Niall C; van Hazel, Guy; Zalcberg, John; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Northern Clinical School: Kolling Institute; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreSingle-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis, European Journal of Cancer, vol.47, 12, 2011,pp 1826-1836